SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

A sharp rally and rising volume have sparked breakout talk, with traders split between expecting further momentum and warning of a pump-and-dump or renewed selling pressure. Bullish discussion also centers on Starknets privacy and Bitcoin DeFi features, post-quantum security, and its potential shift from an Ethereum L2 toward an independent L1.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

Trumps claimed agreement for Russian diesel shipments is prompting debate over whether added fuel supply could ease crude prices, while traders also focus on Strait of Hormuz disruption claims and question official accounts of the shipping situation. The discussion is split between supply-relief concerns and bullish positioning on geopolitical risk.

Zillow Group, Inc. engages in the provision of real estate and home-related information marketplaces on mobile and the web. The company was founded by Richard N. Barton and Lloyd D. Frink in December 2004 and is headquartered in Seattle, WA.

Zillow Group Inc - Ordinary Shares - Class C

Zillow Group Inc Class C

Zillows latest earnings and reduced residential outlook are driving discussion, with traders weighing continued revenue growth against slowing housing activity, high mortgage rates and affordability pressures. Bulls view the selloff as excessive given the companys growth initiatives, while bears see weak transaction volume and cautious guidance as ongoing headwinds.

iShares Trust - iShares 7-10 Year Treasury Bond ETF

iShares 7-10 Year Treasury Bond ETF

Rising Treasury yields and expectations for rates to stay higher for longer are driving attention, with inflation concerns, oil prices and possible Fed hikes weighing on intermediate-term bond prices. Traders are divided between buying IEF on hopes yields will normalize and avoiding or shorting it while yields may rise further.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.

Cardano

Cardanos rebound has sparked breakout and short-squeeze speculation, with traders watching resistance and debating whether the move can hold. Some cite adoption developments such as RealFi and enterprise or payments partnerships, while skeptics warn that gains may fade and question the rallys volume and staying power.

Robinhood GLD is a tokenized representation of SPDR Gold Shares (GLD) common stock, issued on Robinhood Chain, Robinhood's own blockchain built to bring tokenized real-world assets on-chain. Each token is designed to track the price of the underlying GLD share, giving holders on-chain price exposure to SPDR Gold Shares's stock. The token is freely transferable and composable across the Robinhood Chain ecosystem. It's part of Robinhood's broader initiative to expand access to tokenized U.S. equities via blockchain technology, alongside a wider lineup of tokenized stock tokens launching on the same network.

GoldCoin

Gold is drawing attention amid a sharp pullback tied to rising Treasury yields, a stronger U.S. dollar, and expectations of further Fed tightening. Traders are divided between expecting more downside and viewing support as a buying opportunity, while some still see gold as a longer-term hedge against debt and currency debasement.

Arbitrum is one of the leading Ethereum scaling solutions bringing cheap transactions to tens of thousands of users in an environment that feels very similar to Ethereum. It is an optimistic rollup and the leading L2 in terms of TVL. Some of the largest dApps live on Arbitrum include GMX, Radiant, Uniswap V3, and Gains Network.

Arbitrum

Robinhoods use of Arbitrum for tokenized assets is fueling interest in the networks adoption and potential fee growth, but traders disagree on whether that activity will benefit ARB holders. Skeptics point to weak token value capture and ongoing unlocks as reasons the token may lag despite ecosystem growth.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

RHs quarterly results and outlook are driving attention: traders point to an adjusted earnings beat and improved full-year revenue-growth forecast, while skeptics argue tariff refunds boosted the results and question underlying demand and the sales outlook. The reaction is divided, with some viewing the report as evidence of a recovery and others expecting continued pressure on the housing-sensitive luxury furniture business.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Discussion centers on reports that Trump Media scrapped a planned CRO-focused treasury venture with Crypto.com, with many traders viewing the move as negative. The reaction is compounded by long-running concerns about token dilution and previously unburned coins, though some holders see the selloff as a buying opportunity.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDashs autonomous-delivery expansion is drawing attention, with traders discussing drone and UK robot-delivery plans alongside concerns about labor costs and whether the companys growth justifies its valuation; bullish momentum chatter is tempered by criticism over fees and a proposed DashPass class action. No listed article directly verifies the catalyst.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

argenx Meets Primary Endpoint in Phase II Celiac Disease Study

ARGX's FB102 achieves its primary endpoint in a phase II celiac disease study, paving the way for late-stage development despite a nearly 12% stock drop.

EDIT Set to Begin First-in-Human Study in Hypercholesterolemia 

Editas Medicine gains approval to launch the first-in-human phase I/II study of EDIT-401 in Australia, targeting LDL cholesterol through gene editing.

Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio

VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.

ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Study 

argenx shares tumble 12% after discontinuing its late-stage Sjogren's disease study, while positive FB102 data in celiac disease offer a contrasting pipeline development.

Here's Why You Should Add LPCN Stock to Your Portfolio Now

Lipocine's Tlando royalties, Brlizio's phase III trial and broader pipeline offer multiple potential growth drivers and catalysts.

Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash

RARE enters into an agreement to sell a Rare Pediatric Disease PRV for $210M, adding non-dilutive cash as it advances rare-disease therapies.

ETON Stock Surges 108% in Six Months: Here's What You Need to Know

Eton's sales surge, raised 2026 outlook and expanding rare-disease portfolio are boosting confidence in its growth.

PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal

Pacira expands Exparel's European reach through Molteni, adding new markets and revenue streams, with the first commercial sale in Europe expected in 2027.

Here's How Much $100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today

Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 20 years by 5.0% on an annualized basis producing an average annual return of 14.01%. Currently, Alnylam Pharmaceuticals has a marketread more...

AMVUTTRA (vutrisiran) Play by Play Initiative Highlights Former Athletes Stories to Shine a Light on the Often-Missed Signs of ATTR-CM

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the launch of AMVUTTRA (vutrisiran) Play by Play, a U.S. educational initiative featuring former professional athletes living with the cardiomyopathy of transthyretin-mediated amyloidosis (ATTR-CM...

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002, and is headquartered in Cambridge, MA.

Alnylam Pharmaceuticals Inc

IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY

Equity

Neutral Sentiment

Track ALNY stock price, charts, news and real-time market activity on Stocktwits. Join the ALNY message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Alnylam Pharmaceuticals Inc stock.

ALNY Stock Price Today - Alnylam Pharmaceuticals Inc News, Charts, Retail Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

$ALNY well… I found that alny’s competitors phase 3 failed therefore alny went down since they are similar.
The Phase III CARDIO-TTRansform trial for Wainua (eplontersen) did not meet its primary efficacy endpoint of reducing cardiovascular mortality and recurrent cardiovascular events compared to placebo. 

AstraZeneca
Trial Overview and Findings
Primary Endpoint: The study evaluated adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) over a period of up to 140 weeks. Adding Wainua to the standard of care did not show a statistically

Feed

News

Sentiment

Earnings

Fundamentals

Info

ALNY Alnylam Pharmaceuticals Inc

Fundamentals

Latest ALNY News